In a phase 2 open-label platform trial in 41 patients with MASH, LYS006 plus tropifexor for 12 weeks led to pruritus in 62% (primary endpoint: safety); other adverse events were similar to LYS006 alone. ALT and liver fat fell more with the combination; fibrosis markers did not.
RCTn = 41
Frias et al. Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis